Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Comment by Mole101on Aug 18, 2021 1:26pm
138 Views
Post# 33724180

RE:RE:RE:RE:Massive rollback coming

RE:RE:RE:RE:Massive rollback coming

Great time to buy again, I increased my position to over 1.2 million,There are lots of things happening and positive NRs coming our way ,We should see them lining up very soon ..with the Boston group on board, Rudi Tanzi heading the advisory board and a new CEO coming up in the nest few months and results from the cell line development for PMN310...Not happy to see such a share dilution but that’s the price to pay if they are going to move on with the science.. let’s hope immunity tests become mainstream and We can generate some decent revenues on that side of the business


It would be totally naive to think this wasn't going to happen, if they are able to cover the total offering PMN will have close to 30 million cash .. please reminded me when was the last time We were on this position.. I'm looking forward and there will be plenty of time ahead to make some decent $$$ before that dreaded reversed split may happen.




quote=Thenorth1990]Only serology news can save us pr what until ph1 I guess[/quote]
 

<< Previous
Bullboard Posts
Next >>